Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBT777101 in Rheumatoid Arthritis
NCT06201416Phase 1Recruiting
- Sponsor
- Sonoma Biotherapeutics
- Start
- Mar 2024
- Primary completion
- Nov 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of SBT777101 in rheumatoid arthritis (RA) (4 cohorts), sponsored by Sonoma Biotherapeutics. Primary endpoints: Adverse Events at 48 weeks and Dose-Limiting Toxicities at 28 days. Started Mar 2024; status: recruiting.
02
Drugs
SBT777101
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06201416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06201416.